| |
Weight Change in NEAT-022, Switch to dolutegravir from boosted PI, 96 weeks at Glasgow 2018
|
| |
| |
Download the PDF here
Switch to dolutegravir (DTG) from a boosted protease (PI/r) associated with significant weight gain over 48 weeks in NEAT-022, a randomized 96-week trial
Glasgow 2018
In NEAT-022, participants on protease-inhibitor-based ART were randomized to immediate-switch or deferred-switch to DTG. Both groups experienced weight gain though this, was less than 1.25 kg over 96 weeks [15].
We performed a retrospective analysis on an adult, virologically suppressed HIV cohort in London, UK, to assess the impact on weight of switching to a DTG-containing or RAL-containing regimen.
|
|
| |
| |
|
|
|
